Takashi Izumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Izumi has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
Masahiro Nishihori
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi
24 shared publicationsToshihiko Wakabayashi
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
20 shared publicationsYoshio Araki
Department of Neurosurgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
20 shared publicationsShunsaku Goto
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi
18 shared publicationsKinya Yokoyama
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
17 shared publicationsRyuta Saito
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi
16 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 54
Effectiveness and safety of the Sugita clip for ruptured and unruptured intracranial aneurysms: A retrospective cohort study
Background: The long-term outcomes, adverse events, and occlusion rates of the Sugita clip remain unknown. This study evaluated the effectiveness and safety of the Sugita clip by assessing its outcomes and related complications. Methods: Patients who underwent cerebral aneurysm clipping for ruptured or unruptured cerebral aneurysms using the Sugita clip at Nagoya University Hospital and its affiliated facilities between January 01, 2016, and December 31, 2017, were enrolled. We retrospectively investigated patient background, operative information, intraoperative and perioperative complications, device malfunctions, occlusion and parent artery patency rates, and postoperative modified Rankin scale (mRS). We divided patients into two groups based on postoperative mRS to investigate factors that cause deterioration in neurological prognosis. Results: In total, 228 patients with unruptured intracranial aneurysms (UIAs) and 364 with ruptured intracranial aneurysms (RIAs) were included. Concerning postoperative mRS (91–365 days), 223 patients with UIAs and 258 with RIAs had good outcomes (mRS 0–2). Regarding device safety, there were no reports of aneurysm recurrence, parent artery occlusion due to clip slippage, foreign body reactions in the surrounding brain tissue, or device malfunctions. Factors that affected neurological outcomes in UIAs included perioperative hemorrhagic and ischemic complications. Contrastingly, in RIAs, age, Hunt and Kosnik grade, World Federation of Neurosurgical Societies (WFNS) grade, and perioperative ischemic complications were found to affect neurological prognosis. Conclusion: Postoperative mRS of patients who underwent aneurysm surgery using the Sugita clip was comparable to that of global treatment, with no device-related complications, supporting the effectiveness and safety of the Sugita clip.
- 30 January 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 54
Open AccessEffectiveness and safety of the Sugita clip for ruptured and unruptured intracranial aneurysms: A retrospective cohort study
Background: The long-term outcomes, adverse events, and occlusion rates of the Sugita clip remain unknown. This study evaluated the effectiveness and safety of the Sugita clip by assessing its outcomes and related complications. Methods: Patients who underwent cerebral aneurysm clipping for ruptured or unruptured cerebral aneurysms using the Sugita clip at Nagoya University Hospital and its affiliated facilities between January 01, 2016, and December 31, 2017, were enrolled. We retrospectively investigated patient background, operative information, intraoperative and perioperative complications, device malfunctions, occlusion and parent artery patency rates, and postoperative modified Rankin scale (mRS). We divided patients into two groups based on postoperative mRS to investigate factors that cause deterioration in neurological prognosis. Results: In total, 228 patients with unruptured intracranial aneurysms (UIAs) and 364 with ruptured intracranial aneurysms (RIAs) were included. Concerning postoperative mRS (91–365 days), 223 patients with UIAs and 258 with RIAs had good outcomes (mRS 0–2). Regarding device safety, there were no reports of aneurysm recurrence, parent artery occlusion due to clip slippage, foreign body reactions in the surrounding brain tissue, or device malfunctions. Factors that affected neurological outcomes in UIAs included perioperative hemorrhagic and ischemic complications. Contrastingly, in RIAs, age, Hunt and Kosnik grade, World Federation of Neurosurgical Societies (WFNS) grade, and perioperative ischemic complications were found to affect neurological prognosis. Conclusion: Postoperative mRS of patients who underwent aneurysm surgery using the Sugita clip was comparable to that of global treatment, with no device-related complications, supporting the effectiveness and safety of the Sugita clip.
- 1 September 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 143 (3) , 624-633
RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage
OBJECTIVE: Delayed cerebral ischemia (DCI) is a crucial determinant of the prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). In Japan, fasudil has traditionally been used to prevent cerebral vasospasm after aSAH. The effectiveness of clazosentan, a selective endothelin receptor A antagonist, in preventing cerebral vasospasm, a significant contributor to DCI, was recently demonstrated. This study aimed to compare the efficacy and safety of perioperative management using clazosentan- and fasudil-based therapies. METHODS: This multicenter, retrospective observational cohort study included 466 patients with aSAH. Patients were categorized into two groups based on the perioperative management administered: clazosentan or fasudil. Data on patient characteristics, treatment outcomes (assessed using the modified Rankin Scale [mRS] at discharge), and complications (including angiographic cerebral vasospasm, vasospasm-related DCI, pulmonary complications, hypotension, brain edema, and de novo intracerebral hemorrhage) were collected. Statistical analyses were conducted using inverse probability of treatment weighting to adjust for selection bias. RESULTS: Clazosentan was significantly more effective than fasudil in preventing angiographic cerebral vasospasm (33.7% of fasudil-treated patients had vasospasm vs 15.4% of clazosentan-treated patients, p < 0.001) and vasospasm-related DCI (10.2% fasudil vs 4.4% clazosentan, p = 0.007). This improved effectiveness resulted in significantly better outcomes at discharge (50.5% of fasudil-treated patients had an mRS score of 0–2 vs 62.2% of clazosentan-treated patients, p = 0.005). Although clazosentan has been reportedly associated with fluid retention complications, no significant differences in the incidence rates of pulmonary complications or brain edema were found between the groups in this study, likely because of improved fluid management protocols. Clazosentan may also be effective in severe cases or for use in elderly patients aged ≥ 75 years. CONCLUSIONS: Clazosentan outperformed fasudil in preventing cerebral vasospasm and improving overall outcomes in patients with aSAH. Despite initial concerns regarding fluid retention, appropriate perioperative management mitigated these risks, making clazosentan a superior treatment option across different patient groups.
- 1 September 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 143 (3) , 624-633
RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage
OBJECTIVE: Delayed cerebral ischemia (DCI) is a crucial determinant of the prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). In Japan, fasudil has traditionally been used to prevent cerebral vasospasm after aSAH. The effectiveness of clazosentan, a selective endothelin receptor A antagonist, in preventing cerebral vasospasm, a significant contributor to DCI, was recently demonstrated. This study aimed to compare the efficacy and safety of perioperative management using clazosentan- and fasudil-based therapies. METHODS: This multicenter, retrospective observational cohort study included 466 patients with aSAH. Patients were categorized into two groups based on the perioperative management administered: clazosentan or fasudil. Data on patient characteristics, treatment outcomes (assessed using the modified Rankin Scale [mRS] at discharge), and complications (including angiographic cerebral vasospasm, vasospasm-related DCI, pulmonary complications, hypotension, brain edema, and de novo intracerebral hemorrhage) were collected. Statistical analyses were conducted using inverse probability of treatment weighting to adjust for selection bias. RESULTS: Clazosentan was significantly more effective than fasudil in preventing angiographic cerebral vasospasm (33.7% of fasudil-treated patients had vasospasm vs 15.4% of clazosentan-treated patients, p < 0.001) and vasospasm-related DCI (10.2% fasudil vs 4.4% clazosentan, p = 0.007). This improved effectiveness resulted in significantly better outcomes at discharge (50.5% of fasudil-treated patients had an mRS score of 0–2 vs 62.2% of clazosentan-treated patients, p = 0.005). Although clazosentan has been reportedly associated with fluid retention complications, no significant differences in the incidence rates of pulmonary complications or brain edema were found between the groups in this study, likely because of improved fluid management protocols. Clazosentan may also be effective in severe cases or for use in elderly patients aged ≥ 75 years. CONCLUSIONS: Clazosentan outperformed fasudil in preventing cerebral vasospasm and improving overall outcomes in patients with aSAH. Despite initial concerns regarding fluid retention, appropriate perioperative management mitigated these risks, making clazosentan a superior treatment option across different patient groups.
- 21 August 2025
- Published by SAGE Publications in Interventional Neuroradiology
Outcomes of stent-assisted coil embolization of intracranial aneurysms with a small parental vessel diameter
Background: Stent-assisted coil embolization (SACE) is widely used for treating cerebral aneurysms, particularly bifurcation aneurysms. Although stents are typically indicated for parent vessels larger than 2 mm, their use in small-diameter vessels ( 5.5 mm was identified as a risk factor for perioperative ischemic complications. Conclusion: SACE can be safely performed in patients with SD parent vessels without increasing ischemic complications. However, there was only a trend toward higher frequency of intraoperative thrombi in the SD group, highlighting the need for preventive measures and prompt intervention. Having a wide neck diameter > 5.5 mm was identified a risk factor for periprocedural ischemic complications in the SD group.
- 21 August 2025
- Published by SAGE Publications in Interventional Neuroradiology
Outcomes of stent-assisted coil embolization of intracranial aneurysms with a small parental vessel diameter
Background: Stent-assisted coil embolization (SACE) is widely used for treating cerebral aneurysms, particularly bifurcation aneurysms. Although stents are typically indicated for parent vessels larger than 2 mm, their use in small-diameter vessels ( 5.5 mm was identified as a risk factor for perioperative ischemic complications. Conclusion: SACE can be safely performed in patients with SD parent vessels without increasing ischemic complications. However, there was only a trend toward higher frequency of intraoperative thrombi in the SD group, highlighting the need for preventive measures and prompt intervention. Having a wide neck diameter > 5.5 mm was identified a risk factor for periprocedural ischemic complications in the SD group.
- Open Access
- 13 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3403
Emerging Advances in the Management of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Narrative Review
Background/Objectives: Aneurysmal subarachnoid hemorrhage (aSAH) remains a life-threatening cerebrovascular event with high rates of mortality and long-term morbidity. Among its complications, delayed cerebral ischemia (DCI) is a major contributor to poor clinical outcomes. Although cerebral vasospasm has traditionally been considered the primary mechanism underlying DCI, recent studies have revealed the multifactorial nature of this condition. This review aims to provide a comprehensive overview of the pathophysiology, preventive strategies, and current treatment options for DCI following aSAH. Methods: A narrative literature review was conducted using the PubMed database to identify peer-reviewed articles relevant to the prevention and treatment of DCI following aSAH. The search strategy employed the following terms: (“Subarachnoid Hemorrhage” [MeSH]) AND “Delayed Cerebral Ischemia” AND (“Prevention and Control” [Subheading] OR “Secondary Prevention” [MeSH]). This search strategy was designed to capture studies addressing both pharmacological and non-pharmacological preventive measures for DCI. Results: A comprehensive PubMed search identified a total of 113 relevant articles. Among these, 40 publications primarily addressed pharmacological interventions, while 22 focused on neuromonitoring techniques. An additional 20 articles explored the pathophysiological mechanisms underlying DCI, and 15 involved preclinical studies utilizing animal models. The remaining 16 articles encompassed diverse topics, including prophylactic endovascular therapies, newly proposed definitions of DCI, treatment algorithm development, functional outcome analyses, and entries in clinical trial registries. Emerging evidence highlights that vasospasm alone does not account for all cases of DCI. Pharmacological approaches such as nimodipine, clazosentan, and fasudil have shown varying degrees of efficacy. Circulatory management and removal of subarachnoid hematoma via CSF drainage or thrombolytics may reduce DCI risk, although their impact on long-term neurological outcomes remains controversial. Endovascular therapy and adjunctive agents such as cilostazol or anticoagulants have demonstrated potential but require further validation through large-scale trials. Conclusions: Effective DCI prevention and treatment require a multimodal approach targeting diverse pathological mechanisms beyond vasospasm. Improved risk stratification, early detection, and individualized therapy are essential for advancing the management of patients with aSAH.
- 13 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3403
Open AccessEmerging Advances in the Management of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Narrative Review
Background/Objectives: Aneurysmal subarachnoid hemorrhage (aSAH) remains a life-threatening cerebrovascular event with high rates of mortality and long-term morbidity. Among its complications, delayed cerebral ischemia (DCI) is a major contributor to poor clinical outcomes. Although cerebral vasospasm has traditionally been considered the primary mechanism underlying DCI, recent studies have revealed the multifactorial nature of this condition. This review aims to provide a comprehensive overview of the pathophysiology, preventive strategies, and current treatment options for DCI following aSAH. Methods: A narrative literature review was conducted using the PubMed database to identify peer-reviewed articles relevant to the prevention and treatment of DCI following aSAH. The search strategy employed the following terms: (“Subarachnoid Hemorrhage” [MeSH]) AND “Delayed Cerebral Ischemia” AND (“Prevention and Control” [Subheading] OR “Secondary Prevention” [MeSH]). This search strategy was designed to capture studies addressing both pharmacological and non-pharmacological preventive measures for DCI. Results: A comprehensive PubMed search identified a total of 113 relevant articles. Among these, 40 publications primarily addressed pharmacological interventions, while 22 focused on neuromonitoring techniques. An additional 20 articles explored the pathophysiological mechanisms underlying DCI, and 15 involved preclinical studies utilizing animal models. The remaining 16 articles encompassed diverse topics, including prophylactic endovascular therapies, newly proposed definitions of DCI, treatment algorithm development, functional outcome analyses, and entries in clinical trial registries. Emerging evidence highlights that vasospasm alone does not account for all cases of DCI. Pharmacological approaches such as nimodipine, clazosentan, and fasudil have shown varying degrees of efficacy. Circulatory management and removal of subarachnoid hematoma via CSF drainage or thrombolytics may reduce DCI risk, although their impact on long-term neurological outcomes remains controversial. Endovascular therapy and adjunctive agents such as cilostazol or anticoagulants have demonstrated potential but require further validation through large-scale trials. Conclusions: Effective DCI prevention and treatment require a multimodal approach targeting diverse pathological mechanisms beyond vasospasm. Improved risk stratification, early detection, and individualized therapy are essential for advancing the management of patients with aSAH.
- Open Access
- 1 April 2025
- Published by MDPI AG in Preprints.org
Perioperative Management in Aneurysmal Subarachnoid Hemorrhage; Focus on the Prevention of Delayed Cerebral Ischemia
Background: Aneurysmal subarachnoid hemorrhage (aSAH) remains a life-threatening cerebrovascular event with high rates of mortality and long-term morbidity. Among its complications, delayed cerebral ischemia (DCI) is a major contributor to poor clinical outcomes. Although cerebral vasospasm has traditionally been considered the primary mechanism underlying DCI, recent studies have revealed the multifactorial nature of this condition. Objective: This review aims to provide a comprehensive overview of the pathophysiology, preventive strategies, and current treatment options for DCI following aSAH. Methods: We performed a narrative review of the literature, focusing on recent findings regarding the etiologies of DCI—including cerebral vasospasm, microvascular spasm, microthrombi, and cortical spreading depolarization—and the effectiveness of various prophylactic and therapeutic interventions. Results: Emerging evidence highlights that vasospasm alone does not account for all cases of DCI. Pharmacological approaches such as nimodipine, clazosentan, and fasudil have shown varying degrees of efficacy. Circulatory management and removal of subarachnoid hematoma via CSF drainage or thrombolytics may reduce DCI risk, although their impact on long-term neurological outcomes remains controversial. Endovascular therapy and adjunctive agents such as cilostazol or anticoagulants have demonstrated potential but require further validation through large-scale trials. Conclusions: Effective DCI prevention and treatment require a multimodal approach targeting diverse pathological mechanisms beyond vasospasm. Improved risk stratification, early detection, and individualized therapy are essential for advancing the management of patients with aSAH.
- 1 April 2025
- Published by MDPI AG in Preprints.org
Open AccessPerioperative Management in Aneurysmal Subarachnoid Hemorrhage; Focus on the Prevention of Delayed Cerebral Ischemia
Background: Aneurysmal subarachnoid hemorrhage (aSAH) remains a life-threatening cerebrovascular event with high rates of mortality and long-term morbidity. Among its complications, delayed cerebral ischemia (DCI) is a major contributor to poor clinical outcomes. Although cerebral vasospasm has traditionally been considered the primary mechanism underlying DCI, recent studies have revealed the multifactorial nature of this condition. Objective: This review aims to provide a comprehensive overview of the pathophysiology, preventive strategies, and current treatment options for DCI following aSAH. Methods: We performed a narrative review of the literature, focusing on recent findings regarding the etiologies of DCI—including cerebral vasospasm, microvascular spasm, microthrombi, and cortical spreading depolarization—and the effectiveness of various prophylactic and therapeutic interventions. Results: Emerging evidence highlights that vasospasm alone does not account for all cases of DCI. Pharmacological approaches such as nimodipine, clazosentan, and fasudil have shown varying degrees of efficacy. Circulatory management and removal of subarachnoid hematoma via CSF drainage or thrombolytics may reduce DCI risk, although their impact on long-term neurological outcomes remains controversial. Endovascular therapy and adjunctive agents such as cilostazol or anticoagulants have demonstrated potential but require further validation through large-scale trials. Conclusions: Effective DCI prevention and treatment require a multimodal approach targeting diverse pathological mechanisms beyond vasospasm. Improved risk stratification, early detection, and individualized therapy are essential for advancing the management of patients with aSAH.
- Open Access
- 26 December 2024
- Published by Springer Nature in Surgical and Radiologic Anatomy
- Vol. 47 (1) , 1-3
Regression of bilateral persistent primitive ophthalmic artery: a case report
Purpose: We report a case of regression of a 2-year-old girl with bilateral primitive ophthalmic arteries (POAs). Case report: The patient presented with a headache and had no visual impairment or visual field abnormalities. Magnetic resonance angiography (MRA) revealed arteries originating bilaterally from the cavernous internal carotid artery segments, diagnosed as persistent POAs. Conclusion: Six months later, MRA revealed decreased origin delineation and five years later, MRA revealed bilateral origin disappearance from the orbit to the periphery.
- 26 December 2024
- Published by Springer Nature in Surgical and Radiologic Anatomy
- Vol. 47 (1) , 1-3
Open AccessRegression of bilateral persistent primitive ophthalmic artery: a case report
Purpose: We report a case of regression of a 2-year-old girl with bilateral primitive ophthalmic arteries (POAs). Case report: The patient presented with a headache and had no visual impairment or visual field abnormalities. Magnetic resonance angiography (MRA) revealed arteries originating bilaterally from the cavernous internal carotid artery segments, diagnosed as persistent POAs. Conclusion: Six months later, MRA revealed decreased origin delineation and five years later, MRA revealed bilateral origin disappearance from the orbit to the periphery.
- Open Access
- 16 December 2024
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (2) , 108202
Postoperative fragmentation and distal migration of Carotid Stent in vascular Eagle Syndrome
- 16 December 2024
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (2) , 108202
Open AccessPostoperative fragmentation and distal migration of Carotid Stent in vascular Eagle Syndrome
- Open Access
- 1 November 2024
- Vol. 86 (4) , 596-607
Efficacy and safety of endovascular coil embolization for unruptured middle cerebral artery aneurysms: middle-term clinical and imaging outcomes with 3 years mean follow-up periods, a 16-year experience
The anatomical characteristics of middle cerebral artery aneurysms make endovascular treatment difficult. This study evaluated the efficacy and safety of endovascular treatment of unruptured middle cerebral artery aneurysm in preventing rupture. A retrospective review of patients who underwent coil embolization for unruptured middle cerebral artery aneurysm between 2006 and 2022 at Nagoya University Hospital with at least 12 months followed up was conducted. Imaging and clinical outcomes were described using the Raymond classification and the modified Rankin Scale, respectively. Good imaging outcome was defined as complete occlusion or neck remnant and clinical outcome as modified Rankin Scale score of 0-2. Patients were divided into initial and recurrent group based on the number of treatments, pre- and poststent groups based on when stents became available in Japan. A total of 77 patients (80 with aneurysms) were included in the final analysis. Their average age was 60.3 years, and their average follow-up period was 38 months. Favorable clinical outcomes were achieved for 96.2% among 66 (97.0%) initial and 11 (91.7%) recurrent aneurysms. Furthermore, good imaging outcomes were obtained in 90.0 %, and 5% had permanent symptomatic ischemic complications. The pre-stent group had a significantly higher proportion of patients with narrow-neck aneurysms than the post-stent group. There were no significant differences in terms of imaging and clinical outcomes or complication rates. The present study demonstrated that endovascular treatment of unruptured middle cerebral artery aneurysm was safe and effective in preventing rupture. The wide-neck aneurysm was also well embolized by using adjunctive technique.
- 1 November 2024
- Vol. 86 (4) , 596-607
Open AccessEfficacy and safety of endovascular coil embolization for unruptured middle cerebral artery aneurysms: middle-term clinical and imaging outcomes with 3 years mean follow-up periods, a 16-year experience
The anatomical characteristics of middle cerebral artery aneurysms make endovascular treatment difficult. This study evaluated the efficacy and safety of endovascular treatment of unruptured middle cerebral artery aneurysm in preventing rupture. A retrospective review of patients who underwent coil embolization for unruptured middle cerebral artery aneurysm between 2006 and 2022 at Nagoya University Hospital with at least 12 months followed up was conducted. Imaging and clinical outcomes were described using the Raymond classification and the modified Rankin Scale, respectively. Good imaging outcome was defined as complete occlusion or neck remnant and clinical outcome as modified Rankin Scale score of 0-2. Patients were divided into initial and recurrent group based on the number of treatments, pre- and poststent groups based on when stents became available in Japan. A total of 77 patients (80 with aneurysms) were included in the final analysis. Their average age was 60.3 years, and their average follow-up period was 38 months. Favorable clinical outcomes were achieved for 96.2% among 66 (97.0%) initial and 11 (91.7%) recurrent aneurysms. Furthermore, good imaging outcomes were obtained in 90.0 %, and 5% had permanent symptomatic ischemic complications. The pre-stent group had a significantly higher proportion of patients with narrow-neck aneurysms than the post-stent group. There were no significant differences in terms of imaging and clinical outcomes or complication rates. The present study demonstrated that endovascular treatment of unruptured middle cerebral artery aneurysm was safe and effective in preventing rupture. The wide-neck aneurysm was also well embolized by using adjunctive technique.
- Open Access
- 15 September 2024
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 64 (9) , 347-351
A Combination Technique of N-butyl-2-cyanoacrylate and Minimal Coils with Flow Control for Parent Artery Occlusion of a Giant Internal Carotid Artery Aneurysm: A Technical Note
Parent artery occlusion for large or giant internal carotid artery aneurysms remains a necessary procedure in the era of flow diverters. Endovascular parent artery occlusion is currently performed using detachable balloons or coils, which are difficult to obtain or costly. At our institution, we have devised a technique for combining n-butyl-2-cyanoacrylate and coils with flow control to solve this problem. Patients who underwent parent artery occlusion for large or giant internal carotid artery aneurysms with a follow-up period of more than 12 months were included. Imaging outcomes were evaluated for complete or incomplete aneurysmal occlusion and with or without aneurysmal shrinkage. The clinical outcome was based on changes in the modified Rankin Scale. Ten patients (ten aneurysms) were included. Their average age and average follow-up period were 68.4 years and 36 months, respectively. Complete occlusion and favorable clinical outcome were observed in all cases. The parent artery occlusion using a combination of coils and n-butyl-2-cyanoacrylate with flow control technique is effective for both imaging and clinical outcomes.
- 15 September 2024
- Published by Japan Neurosurgical Society in Neurologia medico-chirurgica
- Vol. 64 (9) , 347-351
Open AccessA Combination Technique of N-butyl-2-cyanoacrylate and Minimal Coils with Flow Control for Parent Artery Occlusion of a Giant Internal Carotid Artery Aneurysm: A Technical Note
Parent artery occlusion for large or giant internal carotid artery aneurysms remains a necessary procedure in the era of flow diverters. Endovascular parent artery occlusion is currently performed using detachable balloons or coils, which are difficult to obtain or costly. At our institution, we have devised a technique for combining n-butyl-2-cyanoacrylate and coils with flow control to solve this problem. Patients who underwent parent artery occlusion for large or giant internal carotid artery aneurysms with a follow-up period of more than 12 months were included. Imaging outcomes were evaluated for complete or incomplete aneurysmal occlusion and with or without aneurysmal shrinkage. The clinical outcome was based on changes in the modified Rankin Scale. Ten patients (ten aneurysms) were included. Their average age and average follow-up period were 68.4 years and 36 months, respectively. Complete occlusion and favorable clinical outcome were observed in all cases. The parent artery occlusion using a combination of coils and n-butyl-2-cyanoacrylate with flow control technique is effective for both imaging and clinical outcomes.
- 15 July 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (3) , e52-e57
Superselective Angiography of Vasa Vasorum Within Partially Thrombosed Vertebral Aneurysm: A Case Report
BACKGROUND AND IMPORTANCE: Partially thrombosed vertebral artery aneurysms (PTVAs) are rare, most of which are not easy to treat. Furthermore, endovascular treatment of PTVAs may not have favorable outcomes. The relationship between PTVAs and well-developed vasa vasorum (VV), including the mechanism of aneurysm growth, has been reported, but there are no reports of imaging findings by digital subtraction angiography (DSA). In this case, we successfully performed superselective angiography of well-developed VV and evaluated its imaging characteristics. We present the first DSA report of a well-developed VV of PTVA. CLINICAL PRESENTATION: A 54-year-old patient presented with a PTVA that exerted a mass effect on the medulla oblongata. The aneurysm had no cavity due to thrombosis. The 3-dimensional DSA images indicated VV. Superselective angiography of the VV indicated staining of the thrombosed aneurysm and draining into the suboccipital cavernous sinus through the venous VV. Thus, VV embolization with n-butyl cyanoacrylate was performed. After 3 months, the contrast effect of the aneurysm on contrast-enhanced magnetic resonance imaging disappeared and aneurysm shrinkage was observed. CONCLUSION: We successfully identified a VV within PTVA. Superselective VV angiography showed staining of the thrombosed component and venous return draining into the suboccipital cavernous sinus. In this case, the embolization of the VV proved to be an effective endovascular treatment of PTVA, but the safety of this method is a challenge. Further case studies are required to validate this method, and we hope it will evolve into a new treatment of PTVA.
- 15 July 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 96 (3) , e52-e57
Superselective Angiography of Vasa Vasorum Within Partially Thrombosed Vertebral Aneurysm: A Case Report
BACKGROUND AND IMPORTANCE: Partially thrombosed vertebral artery aneurysms (PTVAs) are rare, most of which are not easy to treat. Furthermore, endovascular treatment of PTVAs may not have favorable outcomes. The relationship between PTVAs and well-developed vasa vasorum (VV), including the mechanism of aneurysm growth, has been reported, but there are no reports of imaging findings by digital subtraction angiography (DSA). In this case, we successfully performed superselective angiography of well-developed VV and evaluated its imaging characteristics. We present the first DSA report of a well-developed VV of PTVA. CLINICAL PRESENTATION: A 54-year-old patient presented with a PTVA that exerted a mass effect on the medulla oblongata. The aneurysm had no cavity due to thrombosis. The 3-dimensional DSA images indicated VV. Superselective angiography of the VV indicated staining of the thrombosed aneurysm and draining into the suboccipital cavernous sinus through the venous VV. Thus, VV embolization with n-butyl cyanoacrylate was performed. After 3 months, the contrast effect of the aneurysm on contrast-enhanced magnetic resonance imaging disappeared and aneurysm shrinkage was observed. CONCLUSION: We successfully identified a VV within PTVA. Superselective VV angiography showed staining of the thrombosed component and venous return draining into the suboccipital cavernous sinus. In this case, the embolization of the VV proved to be an effective endovascular treatment of PTVA, but the safety of this method is a challenge. Further case studies are required to validate this method, and we hope it will evolve into a new treatment of PTVA.